Comparing Tauriga Sciences (TAUG) & USANA Health Sciences (USNA)

Share on StockTwits

Tauriga Sciences (OTCMKTS:TAUG) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

52.2% of USANA Health Sciences shares are owned by institutional investors. 6.2% of Tauriga Sciences shares are owned by company insiders. Comparatively, 48.0% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Tauriga Sciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Profitability

This table compares Tauriga Sciences and USANA Health Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tauriga Sciences N/A -59.23% -30.54%
USANA Health Sciences 7.57% 30.37% 22.10%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tauriga Sciences and USANA Health Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tauriga Sciences 0 0 0 0 N/A
USANA Health Sciences 0 0 2 0 3.00

USANA Health Sciences has a consensus target price of $135.00, indicating a potential upside of 14.69%. Given USANA Health Sciences’ higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Tauriga Sciences.

Valuation and Earnings

This table compares Tauriga Sciences and USANA Health Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tauriga Sciences N/A N/A -$30,000.00 N/A N/A
USANA Health Sciences $1.05 billion 2.73 $62.53 million $4.06 28.99

USANA Health Sciences has higher revenue and earnings than Tauriga Sciences.

Summary

USANA Health Sciences beats Tauriga Sciences on 10 of the 10 factors compared between the two stocks.

Tauriga Sciences Company Profile

Tauriga Sciences, Inc. produces, licenses, and sells lip balm products under the HerMan brand name. The company was founded in 2001 and is based in New York, New York.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé?beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for Tauriga Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tauriga Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply